Drugs / BCD-063
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02753088 | Oct 2013 → Nov 2015 | relapsing-remitting multiple sclerosis | Biocad | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02753088 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day” NCT02753088 ↗ |